Mayumi Lea Anthony
Adult Health · Newark, DENPI 1467711952
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 824 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 47 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,760, 2.1 times the $2,289 reported in 2021. Among adult health clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 824 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Abbott$2K
- Corcept Therapeutics$1K
- Insulet Corporation$1K
- Amgen$1K
- Sanofi-aventis U.S. LLC$954
- plus $8K from 41 others
What the payments were for
- Food & beverage$16,426100%
- Education$550%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$217
- MINIMED 780G$151
- CeQur Simplicity$145
- TZIELD$128
How this compares
$16,482 in reported general payments places this provider in the 95th percentile of 65 adult health providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 399 | $762,342 |
| JardianceEmpagliflozin | 199 | $277,990 |
| TrulicityDulaglutide | 90 | $149,289 |
| RybelsusSemaglutide | 62 | $112,279 |
| FarxigaDapagliflozin Propanediol | 76 | $104,530 |
| MounjaroTirzepatide | 63 | $90,278 |
| Tresiba Flextouch U-100Insulin Degludec | 114 | $88,488 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 52 | $78,801 |
| JanuviaSitagliptin Phosphate | 58 | $60,698 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $48,236 |
| TradjentaLinagliptin | 39 | $42,603 |
| KerendiaFinerenone | 26 | $41,511 |
| Novolog FlexpenInsulin Aspart | 105 | $34,826 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 48 | $33,602 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 169 | $31,671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $2,380 | $913,426516 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $353 | $326,878249 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $590 | $247,690171 claims |
| AstraZenecaFarxiga | $264 | $104,53076 claims |
| MerckJanuvia, Janumet | $298 | $89,07977 claims |
| BayerKerendia | $654 | $41,51126 claims |
| AbbVieSynthroid | $572 | $15,291169 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $348 | $7,947684 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 65 adult health providers in Delaware.
Other adult health in Newark
- Andrea ForsythNewark$3K
- Leslie VerucciNewark$3K
- Kathe Hefner-EricksonNewark$2K
- Rachelle DambmanNewark$2K
- Elizabeth WallsNewark$1K
- Nicole StipoNewark$656
- Lorraine Nowakowski-GrierNewark$209
- Jessica JohnsonNewark$181
- Stacey ByamNewark$170
- Janet ReidNewark$165
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.